Shifting radiation therapy into the neoadjuvant setting for borderline resectable or locally advanced cholangiocarcinoma offers better patient tolerance and potential improvements in R0 resection rates, according to Ethan B. Ludmir, MD, an associate professor in the Department of Gastrointestinal Radiation Oncology at The University of Texas MD Anderson Cancer Center. Speaking ahead of the 2026 Chicago Cholangiocarcinoma Symposium, Ludmir outlined how radiation therapy practices are evolving from postoperative adjuvant use toward preoperative delivery.
Rationale for Preoperative Radiation in Cholangiocarcinoma
Most existing clinical data support radiotherapy in the adjuvant setting. This paradigm is largely anchored by the phase 2 SWOG S0809 trial (NCT00789958), which evaluated adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma. In these trials, radiation functioned essentially as a cleanup crew for patients with margin-positive resections or other adverse pathologic features, such as pathologic T2 disease or higher or pathologic node positivity.
However, clinicians are increasingly looking to treat patients before surgery. Because distal extrahepatic cholangiocarcinoma often shows up in the head of the pancreas, oncologists frequently extrapolate treatment strategies from pancreatic cancer, a reasonable sister disease. According to Ludmir, patients tend to tolerate neoadjuvant radiation better than adjuvant radiation, making the preoperative approach more patient-centric.
Surgical Field Dynamics and Vascular Margins
Did you know? While adjuvant trials like SWOG S0809 targeted adverse features after surgery, emerging clinical approaches leverage preoperative therapy to improve the likelihood of a complete surgical removal, known as an R0 resection.
Moving radiation before surgery introduces distinct surgical considerations regarding tissue planes. Preoperative radiation influences how surgeons encounter and maneuver through tissue planes around the vasculature in the operating room. This dynamic involves individual practitioner variation and expertise.
Some surgeons in the pancreas space report that neoadjuvant radiation, when administered 6 or 8 weeks before surgery, helps create edematous tissue planes. These planes can assist surgeons in removing disease away from the vasculature, potentially yielding a net positive outcome despite the heterogeneity in how people practice.
Common Questions Regarding Cholangiocarcinoma Radiation Therapy
What was the primary role of radiation in historic cholangiocarcinoma trials?
Historically, trials like the phase 2 SWOG S0809 study used radiotherapy in the adjuvant setting to act as a cleanup crew for patients with margin-positive resections, pathologic T2 disease or higher, or pathologic node positivity.
Why are clinicians looking at pancreatic cancer data for cholangiocarcinoma treatment?
Distal extrahepatic cholangiocarcinoma frequently shows up in the head of the pancreas. Because of this, oncologists view pancreatic cancer as a reasonable sister disease and apply insights regarding patient tolerance and R0 resection benefits to extrahepatic cholangiocarcinoma management.
How does timing affect surgical tissue planes during radiation therapy?
Delivering radiation 6 or 8 weeks before surgery can produce edematous tissue planes. According to select surgeons, these tissue changes may assist in removing disease from nearby vasculature during operations, though practices vary among individual practitioners.
Related reading